{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:20:04Z","timestamp":1787840404320,"version":"build-2784847793"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Vitiligo is an immune-mediated, chronic skin condition that affects both the innate and adaptive immune systems. Antimicrobial peptide overexpression is one of its defining characteristics. Granulysin (GNLY), an antimicrobial peptide, may play a role in the pathogenesis of various autoimmune diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To estimate the serum GNLY levels in vitiligo patients and to correlate those levels with the severity and activity of the disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>This case-control study included 60 non-segmental vitiligo patients (Group A) and a control group of 60 people who were matched for age and sex, appeared to be in good health, and were not suffering from vitiligo (Group B). The serum granulysin levels of all subjects were measured using an enzyme-linked immunosorbent assay.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      When compared to the control group, vitiligo patients had significantly higher serum GNLY levels (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.001). When compared to patients with stable disease, those with active vitiligo had significantly higher serum GNLY levels (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.008). Additionally, there was a positive correlation between the serum GNLY levels and the vitiligo area severity index and vitiligo disease activity scores (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.004 and &lt;0.001, respectively).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Limitations:<\/jats:title>\n                    <jats:p>Study population was relatively small. Evaluation of serum granulysin before and after treatment could have been more beneficial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Blood granulysin levels could contribute to the pathogenesis of vitiligo. A higher serum granulysin level may also be a trustworthy predictor of the severity and progression of a disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/idoj.idoj_386_23","type":"journal-article","created":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T12:18:30Z","timestamp":1714393110000},"page":"431-436","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Serum Granulysin as a Possible Key Marker of Vitiligo Activity and Severity"],"prefix":"10.4103","volume":"15","author":[{"given":"Amany I.","family":"Mustafa","sequence":"first","affiliation":[{"name":"Department of Dermatology, Venereology, and Andrology, Faculty of Medicine, Benha University, Benha, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waleed A. E.","family":"Abdel-Halim","sequence":"additional","affiliation":[{"name":"Department of Clinical and Chemical Pathology, Faculty of Medicine, Benha University, Benha, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha M.","family":"Osman","sequence":"additional","affiliation":[{"name":"Department of Clinical and Chemical Pathology, Faculty of Medicine, Helwan Benha University, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shymaa M.","family":"Rezk","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology, and Andrology, Faculty of Medicine, Benha University, Benha, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,4,29]]},"reference":[{"key":"R1-20250921","doi-asserted-by":"crossref","first-page":"13001","DOI":"10.1038\/s41598-018-31233-8","article-title":"Genetic polymorphisms of GZMB and vitiligo: A genetic association study based on Chinese Han population","volume":"8","author":"Xu","year":"2018","journal-title":"Sci Rep"},{"key":"R2-20250921","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1001\/archderm.139.5.581","article-title":"A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo","volume":"139","author":"Lepe","year":"2003","journal-title":"Arch Dermatol"},{"key":"R3-20250921","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3892\/mmr.2012.1117","article-title":"CD8+T cells from vitiligo perilesional margins induce autologous melanocyte apoptosis","volume":"7","author":"Wu","year":"2013","journal-title":"Mol Med Rep"},{"key":"R4-20250921","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1111\/j.1600-6143.2005.00970.x","article-title":"Granulysin: A novel host defense molecule","volume":"5","author":"Krensky","year":"2005","journal-title":"Am J Transplant"},{"key":"R5-20250921","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.4049\/jimmunol.158.6.2680","article-title":"Processing, subcellular localization, and function of 519 (granulysin), a human late T cell activation molecule with homology to small, lytic, granule proteins","volume":"158","author":"Pena","year":"1997","journal-title":"J Immunol"},{"key":"R6-20250921","doi-asserted-by":"crossref","first-page":"350","DOI":"10.4049\/jimmunol.167.1.350","article-title":"A distinct pathway of cell-mediated apoptosis initiated by granulysin","volume":"167","author":"Kaspar","year":"2001","journal-title":"J Immunol"},{"key":"R7-20250921","doi-asserted-by":"crossref","first-page":"5243","DOI":"10.4049\/jimmunol.174.9.5243","article-title":"Granulysin, a cytolytic molecule, is also a chemoattractant and proinflammatory activator","volume":"174","author":"Deng","year":"2005","journal-title":"J Immunol"},{"key":"R8-20250921","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/j.1365-2133.2004.05925.x","article-title":"Involvement of granulysin-producing T cells in the development of superficial microbial folliculitis","volume":"150","author":"Oono","year":"2004","journal-title":"Br J Dermatol"},{"key":"R9-20250921","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/j.1365-2133.2005.06849.x","article-title":"The role of CD4 and CD8 cytotoxic T lymphocytes in the formation of viral vesicles","volume":"153","author":"Morizane","year":"2005","journal-title":"Br J Dermatol"},{"key":"R10-20250921","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jaad.2003.10.679","article-title":"Lesional T cells and dermal dendrocytes in psoriasis plaque express increased levels of granulysin","volume":"51","author":"Raychaudhuri","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"R11-20250921","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1600-0560.2007.00892.x","article-title":"Involvement of granzyme B and granulysin in the cytotoxic response in lichen planus","volume":"35","author":"Ammar","year":"2008","journal-title":"J Cutan Pathol"},{"key":"R12-20250921","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jdermsci.2013.08.009","article-title":"Serum granulysin as a possible key marker of the activity of alopecia areata","volume":"73","author":"Ono","year":"2014","journal-title":"J Dermatol Sci"},{"key":"R13-20250921","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/nm.1884","article-title":"Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"14","author":"Chung","year":"2008","journal-title":"Nat Med"},{"key":"R14-20250921","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1600-0749.2006.00355.x","article-title":"The definition and assessment of vitiligo: A consensus report of the Vitiligo European Task Force","volume":"20","author":"Ta\u00efeb","year":"2007","journal-title":"Pigment Cell Res"},{"key":"R15-20250921","doi-asserted-by":"crossref","first-page":"750342","DOI":"10.1155\/2011\/750342","article-title":"Disease severity indexes and treatment evaluation criteria in vitiligo","volume":"2011","author":"Kawakami","year":"2011","journal-title":"Dermatol Res Pract"},{"key":"R16-20250921","doi-asserted-by":"crossref","first-page":"315","DOI":"10.4103\/0378-6323.26722","article-title":"Scoring systems in dermatolog","volume":"72","author":"Bhor","year":"2006","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R17-20250921","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.det.2016.11.014","article-title":"Vitiligo pathogenesis and emerging treatments","volume":"35","author":"Rashighi","year":"2017","journal-title":"Dermatol Clin"},{"key":"R18-20250921","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1111\/jocd.13908","article-title":"Elevated serum level of interleukin-15 in vitiligo patients and its correlation with disease severity but not activity","volume":"20","author":"Atwa","year":"2021","journal-title":"J Cosmet Dermatol"},{"key":"R19-20250921","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1189\/jlb.0409222","article-title":"Induction of granulysin in CD8+T cells by IL-21 and IL-15 is suppressed by human immunodeficiency virus-1","volume":"86","author":"Hogg","year":"2009","journal-title":"J Leukoc Biol"},{"key":"R20-20250921","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/pcmr.12355","article-title":"Increased circulating Th17 cells and elevated serum levels of TGF-beta and IL-21 are correlated with human non-segmental vitiligo development","volume":"28","author":"Zhou","year":"2015","journal-title":"Pigment Cell Melanoma Res"},{"key":"R21-20250921","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4049\/jimmunol.1900027","article-title":"The role of memory CD8+T cells in vitiligo","volume":"203","author":"Riding","year":"2019","journal-title":"J Immunol"},{"key":"R22-20250921","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/hepr.12421","article-title":"Serum granulysin levels as a predictor of serious telaprevir-induced dermatological reactions","volume":"45","author":"Suda","year":"2015","journal-title":"Hepatol Res"},{"key":"R23-20250921","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1002\/eji.200323977","article-title":"Granulysin in human serum as a marker of cell-mediated immunity","volume":"33","author":"Ogawa","year":"2003","journal-title":"Eur J Immunol"},{"key":"R24-20250921","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1046\/j.1523-1747.2000.00828.x","article-title":"Role of cytotoxic T cells in chronic alopecia areata","volume":"114","author":"Bodemer","year":"2000","journal-title":"J Invest Dermatol"},{"key":"R25-20250921","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1471-4159.2004.02487.x","article-title":"Regulation of RANTES\/CCL5 expression in human astrocytes by interleukin-1 and interferon-beta","volume":"90","author":"Kim","year":"2004","journal-title":"J Neurochem"},{"key":"R26-20250921","first-page":"665","article-title":"Expression of CXCL12 on pseudopalisading cells and proliferating microvessels in glioblastomas: An accelerated growth factor in glioblastomas","volume":"34","author":"Komatani","year":"2009","journal-title":"Int J Oncol"},{"key":"R27-20250921","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/j.1365-4632.2006.02744.x","article-title":"Increased tumor necrosis factor alpha (TNF-alpha) and interleukin 1 alpha (IL1-alpha) levels in the lesional skin of patients with nonsegmental vitiligo","volume":"45","author":"Birol","year":"2006","journal-title":"Int J Dermatol"},{"key":"R28-20250921","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1046\/j.1523-1747.2001.01363.x","article-title":"HLA-A2 restricted, melanocyte-specific CD8(+) T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA\/MART1","volume":"116","author":"Lang","year":"2001","journal-title":"J Invest Dermatol"},{"key":"R29-20250921","doi-asserted-by":"crossref","first-page":"e37513","DOI":"10.1371\/journal.pone.0037513","article-title":"Global activation of CD8+ cytotoxic T lymphocytes correlates with an impairment in regulatory T cells in patients with generalized vitiligo","volume":"7","author":"Lili","year":"2012","journal-title":"PLoS One"},{"key":"R30-20250921","doi-asserted-by":"crossref","first-page":"11429","DOI":"10.3390\/ijms222111429","article-title":"Role of cytokines in vitiligo: Pathogenesis and possible targets for old and new treatments","volume":"22","author":"Custurone","year":"2021","journal-title":"Int J Mol Sci"}],"container-title":["Indian Dermatology Online Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.idoj_386_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:22:11Z","timestamp":1787836931000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.idoj_386_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,29]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/idoj.idoj_386_23","relation":{},"ISSN":["2229-5178","2249-5673"],"issn-type":[{"value":"2229-5178","type":"print"},{"value":"2249-5673","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,29]]},"assertion":[{"value":"2023-05-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}